Acerta Pharma Bv

This study tests a drug called acalabrutinib (ACP-196) in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug by mouth, and researchers monitor safety and how well…

This phase 3 study compares two oral medications, acalabrutinib and ibrutinib, in adults with high-risk chronic lymphocytic leukemia (CLL) who have already received at least one prior treatment. The goal is to see if acalabrutinib is as effective as ibrutinib at delaying cancer p…

This study tests a drug called ACP-196 (acalabrutinib) in 60 adults with chronic lymphocytic leukemia (CLL) whose cancer returned or didn't respond to treatment and who had side effects from another drug, ibrutinib. The goal is to see if ACP-196 can shrink or control the cancer. …

This study tests a drug called acalabrutinib, alone or with other medicines, in people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to see if the drug is safe and can shrink tumors. About 113 adults took part. This is not a …

This early-phase study tests a new drug (acalabrutinib) combined with standard treatments (bendamustine and rituximab, or venetoclax and rituximab) in 72 adults with untreated mantle cell lymphoma. The main goal is to check safety and side effects. Participants must not have had …

This study tests a drug called ACP-196 (acalabrutinib) in 124 adults with mantle cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients' tumors shrink or disappear. Participants take the drug by mouth, and researchers monitor …

This study tests a drug called ACP-196 (acalabrutinib) in adults whose glioblastoma brain tumor has come back after standard treatment. The goal is to see if the drug can shrink or control the tumor. About 24 participants will receive the drug, and their response will be measured…

This early-phase study tests a new drug combination (ceralasertib plus acalabrutinib) in 12 people with high-risk chronic lymphocytic leukemia (CLL) that has come back or not responded to other treatments. The main goal is to check safety and find the right dose. Participants mus…

This study tested a newer targeted drug called acalabrutinib against two standard combination therapies (idelalisib plus rituximab or bendamustine plus rituximab) in 310 adults with chronic lymphocytic leukemia (CLL) that had come back or stopped responding to prior treatment. Th…

This study tests whether adding the drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a certain type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). About 611 adults aged 18 to 75 are participating. The main goal is to see if the combination delay…

This study tests a new drug called acalabrutinib for people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal is to see if the drug is safe and can shrink or control the cancer. Participants take the drug by mouth, and the study tracks side effects and ho…

This study tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) helps people with untreated mantle cell lymphoma live longer without their cancer getting worse. About 635 adults aged 65 and older will take part. The goal is to…